tiprankstipranks
Astellas Pharma Inc (JP:4503)
TSE/TYO:4503
Holding JP:4503?
Track your performance easily

Astellas Pharma (4503) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

4503 Analyst Ratings

Moderate Buy
7Ratings
3 Buy
4 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Astellas
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4503 Stock 12 Month Forecast

Average Price Target

¥1,962.55
▲(25.64% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is ¥1,962.55 with a high forecast of ¥2,113.42 and a low forecast of ¥1,761.19. The average price target represents a 25.64% change from the last price of ¥1,562.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1491":"¥1,491","2114":"¥2,114","1646.75":"¥1,646.8","1802.5":"¥1,802.5","1958.25":"¥1,958.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2113.42360916736,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥2.11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1962.5475072,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥1.96K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1761.1863409728,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥1.76K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1491,1646.75,1802.5,1958.25,2114],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1807.032585320566,1832.5651706411322,1858.0977559616986,1883.6303412822647,1909.1629266028308,1934.695511923397,1960.2280972439632,1985.7606825645294,2011.2932678850955,2036.8258532056616,2062.358438526228,2087.891023846794,{"y":2113.42360916736,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1795.4267313230769,1809.3534626461537,1823.2801939692308,1837.2069252923077,1851.1336566153846,1865.0603879384614,1878.9871192615385,1892.9138505846154,1906.8405819076922,1920.767313230769,1934.6940445538462,1948.620775876923,{"y":1962.5475072,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1779.9374108440616,1778.3748216881231,1776.8122325321847,1775.2496433762462,1773.6870542203078,1772.1244650643694,1770.5618759084307,1768.9992867524923,1767.4366975965538,1765.8741084406154,1764.311519284677,1762.7489301287385,{"y":1761.1863409728,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1731.063,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1615.595,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1621.344,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1604.575,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1605.679,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1492.175,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1515.169,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1554.309,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1621.334,"date":1720742400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1707.44,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1762.235,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1728,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1781.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target¥2,113Average Price Target¥1,963Lowest Price Target¥1,761
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any

Best Analysts Covering Astellas Pharma

Which Analyst Should I Follow If I Want to Buy JP:4503 and Sell After:
1 Month
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+0.17%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +0.17% per trade.
3 Months
xxx
Success Rate
1/3 ratings generated profit
33%
Average Return
-6.97%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -6.97% per trade.
1 Year
Miki SogiBernstein
Success Rate
1/3 ratings generated profit
33%
Average Return
-5.23%
reiterated a buy rating 6 days ago
Copying Miki Sogi's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -5.23% per trade.
2 Years
xxx
Success Rate
1/3 ratings generated profit
33%
Average Return
-5.23%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -5.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4503 Analyst Recommendation Trends

Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
0
1
1
4
4
Buy
2
1
0
0
0
Hold
3
3
4
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
5
7
7
In the current month, 4503 has received 4 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 4503 average Analyst price target in the past 3 months is ¥1,962.55.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

4503 Financial Forecast

4503 Earnings Forecast

Next quarter’s earnings estimate for 4503 is ¥18.49 with a range of ¥10.21 to ¥23.40. The previous quarter’s EPS was ¥20.06. 4503 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 44.08% of the time in the same period. In the last calendar year 4503 has Outperformed its overall industry.
Next quarter’s earnings estimate for 4503 is ¥18.49 with a range of ¥10.21 to ¥23.40. The previous quarter’s EPS was ¥20.06. 4503 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 44.08% of the time in the same period. In the last calendar year 4503 has Outperformed its overall industry.

4503 Sales Forecast

Next quarter’s sales forecast for 4503 is ¥444.31B with a range of ¥415.50B to ¥472.70B. The previous quarter’s sales results were ¥462.50B. 4503 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.91% of the time in the same period. In the last calendar year 4503 has Outperformed its overall industry.
Next quarter’s sales forecast for 4503 is ¥444.31B with a range of ¥415.50B to ¥472.70B. The previous quarter’s sales results were ¥462.50B. 4503 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.91% of the time in the same period. In the last calendar year 4503 has Outperformed its overall industry.

4503 Stock Forecast FAQ

What is JP:4503’s average 12-month price target, according to analysts?
Based on analyst ratings, Astellas Pharma Inc’s 12-month average price target is ¥1,962.55.
    What is JP:4503’s upside potential, based on the analysts’ average price target?
    Astellas Pharma Inc has 25.64% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Astellas Pharma Inc a Buy, Sell or Hold?
          Astellas Pharma Inc has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Astellas Pharma Inc’s share price target?
            The average share price target for Astellas Pharma Inc is ¥1,962.55. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ¥2,113.42 ,and the lowest forecast is ¥1,761.19. The average share price target represents 25.64% Increase from the current price of ¥1,562.
              What do analysts say about Astellas Pharma Inc?
              Astellas Pharma Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of Astellas Pharma Inc?
                To buy shares of JP:4503, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis